October 24, 2016—The Department of Health and Human Services’ final 340B program rule setting standards for calculating ceiling prices and implementing civil monetary penalties for drugmakers that “knowingly” and “intentionally” overcharge covered entities for covered outpatient drugs is a step closer to release.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)